Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-Tocilizumab Polyclonal Antibody

Catalog #:   PAC36902 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA
Accession: CAS: 375823-41-9
Overview

Catalog No.

PAC36902

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

Tocilizumab

Tested applications

ELISA: 1:4000-1:8000

Target

Rabbit polyclonal to Actemra.

Specificity

The product is specific for Tocilizumab. This antibody serves as an excellent positive control for Tocilizumab immunogenicity (ADA) assays.

Concentration

0.72 mg/ml

Purification

Purified by antigen affinity column.

Accession

CAS: 375823-41-9

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.

Background

Tocilizumab (Actemra) is a humanized monoclonal antibody that is developed by Hoffmann–La Roche and Chugai for the treatment of patients with rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. Tocilizumab binds to the interleukin-6 receptor (IL-6R) and blocks its interaction with interleukin 6 (IL-6), hindering IL-6 from exerting its pro-inflammatory effects.

Data Image
References

Key indicators for guiding tocilizumab therapy to prevent orbital decompression surgery in hormone-resistant dysthyroid optic neuropathy., PMID:40510358

The clinical toxicity of advanced therapy medicinal products., PMID:40509780

Unravelling VEXAS syndrome: shedding light on a recently recognised medical condition., PMID:40499953

A rare case report: acute necrotizing encephalopathy and acute fulminant myocarditis., PMID:40495992

Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial., PMID:40480650

Tumefactive demyelination as the first presentation of MOG ab-associated disease., PMID:40479755

Steroid refractory immune-related acute disseminated encephalomyelitis (ADEM) successfully treated with 2nd and 3rd line immunosuppressive therapy., PMID:40473324

Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future., PMID:40463417

[Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report]., PMID:40462437

Tocilizumab-Based Treatment of Microvascular Inflammation in Kidney Transplant Recipients: A Retrospective Study., PMID:40454296

Antibody-mediated Rejection - Treatment Standard., PMID:40440205

Interactions of Probiotics with the Immune Cells of Patients with COVID-19 Pneumonia., PMID:40424990

Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation., PMID:40423982

Anti-MDA5 antibody positive dermatomyositis complicated by interstitial lung disease with an improved outcome: A case report., PMID:40419927

Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review., PMID:40406130

Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves' orbitopathy: a systematic review and meta-analysis., PMID:40404973

[Update of clinical management in autoimmune encephalitis-2004]., PMID:40399061

Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis: A Randomized Clinical Trial., PMID:40388166

Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials., PMID:40378861

Modeling and Optimization of Recombinant Tocilizumab Production From Pichia pastoris Using Response Surface Methodology and Artificial Neural Network., PMID:40371610

Targeting IL-6 in antibody-mediated kidney transplant rejection., PMID:40357502

Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia., PMID:40354592

Dynamics of Modified Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis on the Background of 5-Year Therapy with an Interleukin 6 Receptor Inhibitor., PMID:40353962

Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract., PMID:40345961

Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial., PMID:40340657

Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management., PMID:40324443

Efficacy and safety of Tocilizumab for thyroid eye disease: a systemic review and Meta-analysis., PMID:40304985

Reversible cerebral vasoconstriction syndrome in idiopathic multicentric Castleman disease under treatment with tocilizumab., PMID:40297744

Tocilizumab for Patients with Severe Fever with Thrombocytopenia Syndrome: Tocilizumab Observational SFTS Study-1., PMID:40288904

Short Form-36 psychometric properties in idiopathic inflammatory myopathies: reliability, validity, and responsiveness., PMID:40279268

Desensitization to Tocilizumab in a Patient With Juvenile Idiopathic Arthritis., PMID:40271283

Amyloidosis in Human Inborn Errors of Immunity Predicts Poor Prognosis., PMID:40266382

Anti-GAD65 Antibodies Related Refractory Epilepsy Successfully Treated with Tocilizumab: A Case Report and Systematic Literature Review., PMID:40264689

Efficacy of tocilizumab monotherapy for autoimmune hemolytic anemia associated with idiopathic multicentric Castleman disease: a case-based review., PMID:40257590

Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy., PMID:40255392

Long-term functional prognosis with tocilizumab in severe COVID-19 infection: A multicenter prospective observational study on mechanically ventilated ICU patients in the COVID-19 recovery study II., PMID:40250803

Addressing practical challenges with bispecific antibody therapy in multiple myeloma., PMID:40247652

Tocilizumab and IVIG experience during the service follow-up in patients with severe COVID-19 pneumonia., PMID:40243800

Reply to Saleh, C.; Budincevic, H. Interleukin-6, Tocilizumab and Atherosclerosis. Comment on "Gerasimova et al. Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis. Int. J. Mol. Sci. 2024, 25, 12425"., PMID:40243555

Interleukin-6, Tocilizumab and Atherosclerosis. Comment on Gerasimova et al. Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis. Int. J. Mol. Sci. 2024, 25, 12425., PMID:40243553

Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization., PMID:40233295

Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review., PMID:40227780

A Rapid Systematic Review of U.S. Food and Drug Administration-Authorized COVID-19 Treatments., PMID:40225829

Glucocorticoid boluses followed by tocilizumab in giant cell arteritis patients: effects on peripheral blood monocytes and lymphocytes., PMID:40213553

Epidemiology of aquaporin-4 seropositive neuromyelitis optica spectrum disorder in the Alicante health area, Spain: A population-based study., PMID:40203603

Sonographic study on vessel wall remodelling of the cranial and axillary arteries in giant cell arteritis under treatment: implications for diagnosis of relapses and impact of tocilizumab treatment., PMID:40201971

A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product., PMID:40198544

The cardiovascular effects of interleukin-6 inhibition in patients with severe coronavirus-19 infection., PMID:40173032

The Efficacy and Safety of Hepatitis A Vaccine in Children and Young Adults With an Autoinflammatory Diseases on Canakinumab and Tocilizumab Treatments: A Prospective Observational Controlled Study., PMID:40172610

Mechanism and Efficacy of Etanercept in Treating Autoimmune-like Manifestations of Coronavirus Disease 2019 in elderly individuals., PMID:40168796

Datasheet
$ 354
Product specifications
50 μg 354 100 μg 680

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Tocilizumab Polyclonal Antibody [PAC36902]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only